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The spontaneous transition of Epstein-Barr virus
(EBV) from latency to productive infection is infre-
quent, making its analysis in the resulting mixed
cell populations difficult. We engineered cells to sup-
port this transition efficiently and developed EBV
DNA variants that could be visualized and measured
as fluorescent signals over multiple cell cycles. This
approach revealed that EBV’s productive replication
began synchronously for viral DNAs within a cell but
asynchronously between cells. EBV DNA amplifica-
tion was delayed until early S phase and occurred
in factories characterized by the absence of cellular
DNA and histones, by a sequential redistribution of
PCNA, and by localization away from the nuclear
periphery. The earliest amplified DNAs lacked his-
tones accompanying a decline in four histone chap-
erones. Thus, EBV transits from being dependent
on the cellular replication machinery during latency
to commandeering both that machinery and nuclear
structure for its own reproductive needs.
INTRODUCTION
Epstein-Barr virus (EBV) is a human tumor virus which latently
infects primary B cells, inducing and maintaining their pro-
liferation in cell culture and only infrequently transiting to EBV’s
productive cycle (Sugden, 1984). EBV also infects epithelial cells
to cause several carcinomas. No other herpesvirus displays its
biphasic life cycle as tractably in culture, making EBV a powerful
tool to reveal the steps used by a virus in commandeering its host
to produce viral progeny. Much has been learned about the final
stages of EBV’s productive cycle. The viral proteins needed for
amplification of EBV DNA have been identified functionally
(Chiu et al., 2007; Fixman et al., 1992). These EBV proteins and
multiple cellular factors have been shown to localize to discrete
sites in productively infected nuclei (Amon et al., 2006; Bell et al.,
2000; Daikoku et al., 2005, 2006; Kudoh et al., 2009; Park et al.,
2008). It has also been shown that EBV must transit from its use
of its latent origin of DNA synthesis, oriP, to use two lytic origins,
oriLyt L and R, to support its DNA amplification during a produc-Cell Host &tive cycle (Hammerschmidt and Sugden, 1988). This transition
is infrequently spontaneous and can be induced with various
treatments in different cells (Chang and Liu, 2000; Chasserot-
Golaz et al., 1988; Luka et al., 1979; Takada, 1984; Tovey
et al., 1978; zur Hausen et al., 1978) but is usually inefficient,
making it difficult not only to analyze events during EBV’s pro-
ductive infection but also to distinguish between effects elicited
by EBV and those induced by the treatments themselves. In
addition, measurements of EBV’s productive cycle are often
averaged across an asynchronous population, obscuring events
that occur transiently.
We have examined the transition to and the amplification of
EBV DNA during productive infection in single cells using live-
cell imaging to identify and characterize sequentially processes
that are associatedwith the synthesis of progeny virus. To render
these processes as synchronous as practical and independent
of broadly active agents such as TPA and sodium butyrate, the
host cells were engineered to express EBV’s immediate-early
protein BZLF1 fused to the estrogen receptor ligand-binding
domain (Z-ER). The translocation of Z-ER from the cytoplasm
to the nucleus in cells harboring EBV latently could be induced
by tamoxifen and elicited EBV’s productive cycle (Countryman
and Miller, 1985; Takada et al., 1986). The productive cycle for
two derivatives of EBV, Visible Amplicon and Visible EBV,
following a synchronous induction occurred in either the ongoing
cell cycle or in the subsequent cell cycle. Visible Amplicon
contains the cis-acting viral elements required to participate in
amplification and packaging (Bloss and Sugden, 1994); Visible
EBV was made from the 2089 Bacmid of the B95.8 strain of
EBV (Delecluse et al., 1998). Both EBV derivatives were modified
to contain a polymer of lac operator binding sites (lacO) and to
express the lac repressor (LacI) fused to the tdTomato fluores-
cent protein to render them visible following removal of IPTG
from themedium (Nanbo et al., 2007; Norby et al., 2012; Robinett
et al., 1996). Following treatment with tamoxifen, host cells
supported amplification of the latent, resident plasmids in up
to 60% of the treated cells, which were followed hourly in live
cells for 60 hr. To measure the intensities of the plasmids bound
by the LacI-fluorescent fusions, we developed a computer-
assisted approach, termed Computer-Assisted Plasmid Sum-
mation (CAPS). CAPS uses photometry with subtraction of a
background derived from an annulus of the pixels over multiple
z planes surrounding a given LacI-fluorescent signal of an EBV
derivative after removal of IPTG to measure the intensities of
all chosen signals. CAPS provides functions not found elsewhereMicrobe 14, 607–618, December 11, 2013 ª2013 Elsevier Inc. 607
Figure 1. The Structures of Visible Ampli-
con and Visible EBVBacmid and Their Char-
acterization
(A) A DNA fragment encoding resistance to kana-
mycin, a fusion of LacI-tdTomato fluorescent
protein, and containing 250 copies of lacO sites
was inserted into an EBV-derived amplifiable
plasmid, p3944.
(B) That same fragment was used to substitute for
the eGFP gene of EBV Bacmid 2089 by Red-
mediated homologous recombination. The size of
Visible EBV’s genome is predicted to be approxi-
mately 170 kbp with variable lengths of BamH-W
and terminal repeats (TR) (see also Figure S1A)
(Bloss and Sugden, 1994).
(C) Removing IPTG from cells with Visible EBV
allows binding of LacI-tdTomato fusion and its
detection (red circle) in 3.5 hr.
(D) The released encapsidated Visible Amplicon
and Visible EBV were quantified by qPCR and by
infection of EBV-negative Daudi cells. The ratio of
these measurements yielded their specific in-
fectivities (see also Figure S1).
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cell cycles and measure their potential overlaps with fluores-
cently tagged proteins.
EBV DNA is synthesized using cellular machinery during its
latent phase localized in replication factories that are marked
by PCNA (Leonhardt et al., 2000). Induction of EBV’s productive
cycle led first to dramatic alterations in nuclear morphology
followed later by amplification of EBV DNA. The unlicensed syn-
thesis of EBV’s genome in its productive cycle coincidedwith the
maximal expression of Cdt1/eGFP, revealing that it began in
early S phase (Sakaue-Sawano et al., 2008). EBV’s genome syn-
thesis occurred at distinct sites, which we term ‘‘amplification
factories,’’ in which PCNA was redistributed. The architecture
of the nucleus was reorganized so that cellular DNA and histones
accumulated at its margins while the factories formed internally.
Cellular histones were not detectably associated with the sites of
amplifying viral DNA which correlated with marked declines in
the levels of the cellular histone chaperones, CAF-1a, CAF-1b,
ASF1a, and ASF1b. Nor was PCNA localized to these sites.
These insights explain how EBV evades the cellular machinery
that deposits histones on newly synthesized DNA (Johannsen
et al., 2004). Our time-lapse analyses show that EBV transits
from being a fellow traveler dependent on cellular replication
machinery during latency to commandeering both that machin-
ery and nuclear structure for its own reproductive needs.608 Cell Host & Microbe 14, 607–618, December 11, 2013 ª2013 Elsevier Inc.RESULTS
Developing Plasmids and Cells to
Visualize EBV’s Productive Cycle
To overcome limitations inherent in
studies of heterogeneous populations of
cells, we have engineered two derivatives
of EBV that can be analyzed visually to
follow events in EBV’s productive phase.
These derivatives are detected as single
DNA molecules and followed in real timeover days as they are amplified. One is a Visible Amplicon (Fig-
ure 1A), which contains EBV’s oriLyt, oriP, and terminal repeats.
It also encodes resistance to G418, the LacI fused to the
tdTomato fluorescent protein along with a nuclear localization
signal, and contains 250 binding sites for this LacI-tdTomato
fluorescent fusion. The other, termed Visible EBV, was con-
structed by introducing a DNA fragment encoding kanamycin-
resistance, the LacI-tdTomato fluorescent fusion, and 250
copies of lacO sequence into an intact EBV Bacmid, 2089, to
replace its eGFP gene (Figure 1B and Figure S1A available
online). Both the Visible Amplicon and Visible EBV, when
maintained latently in mammalian cells, could be visualized as
punctate fluorescent signals distributed evenly in the nuclei
following removal of IPTG from the medium (Figures 1C, S1B–
S1D, and S2D).
The Visible Amplicon contains the cis-acting elements (oriLyt,
oriP, and terminal repeats) needed for EBV’s productive cycle
and lacks all other EBV genes. It was therefore introduced into
a derivative of D98/HR1 cells (iD98/HR1), which contains a
variant of EBV that fully supports its productive cycle (Glaser
and Rapp, 1972) and was transduced to express Z-ER. Addition
of tamoxifen to these cells induced EBV’s productive cycle.
The induced cells ultimately released encapsidated polymers
of the Visible Amplicon (Bloss and Sugden, 1994) (Figure 1D).
In parallel, Visible EBV was introduced into clones of a derivative
Figure 2. CAPS Measures Signal Intensities
(A) Typical signals of Visible EBV in live cells contribute a peak pixel intensity of 150 (red) above a background annulus (gray) of about 3,600 units per pixel.
(B) CAPS averages the pixel intensities in the annulus and subtracts that average from each signal pixel and each background pixel to reveal the Gaussian
distribution of Visible EBV’s signal as measured by Gaussian fitting.
(C) CAPS measures the overlap of EBV bound LacI-tdTomato signals with other florescent tags by determining signal intensities (red) as described above and
then scaling both the most intense pixel in each signal to 1 and the radius of the pixels to 1, allowing them to be summed. Summed point sources show a signal
that decreases as the distance from the source increases (lower left). To measure the overlap of another florescent tag, here green, CAPSmeasures intensities of
the same pixels in green, measures the intensities of the pixels in the annulus in green, subtracts their average from all the pixels, sums the corrected intensities
from inside the annulus, and scales them as for the LacI-tdTomato signals. An overlapping point source will have a similar profile as LacI-tdTomato signals;
nonoverlapping signals will not vary systematically but rather will scatter evenly independently of the distance from the source (lower right).
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of these cells with tamoxifen also induced and supported
the complete productive cycle, yielding 1.2 3 107 Visible EBV
DNA-containing particles per ml. Approximately 1 out of 100
DNA-containing particles was infectious (Figure 1D), an
efficiency comparable to that of the B95.8 strain of EBV. The
encapsidated, infectious Visible EBV was also as competent to
infect and transform primary human B cells as wild-type EBV
(Sugden and Mark, 1977). The infected B cells proliferated for
months and displayed punctate genomes when viewed under
a fluorescence microscope following removal of IPTG from the
media (Figure S1D).
Developing CAPS to Measure the Intensities of EBV
DNAs Bound by Fluorescent Proteins
We developed CAPS to measure the intensity of fluorescent
signals in microscopy images in multiple z planes with subtrac-
tion of an annulus background, as has been applied to astronom-
ical images (Mighell, 1999). CAPS has two libraries of code,
found at http://caps.grapheasy.org, and instructions to help
users master them. CAPS displays images of a time series of
16 bit z planes and allows measurements of their signals even
when they are less than 5% of background (Figure 2A). It dis-
plays multiple z planes simultaneously to aid plasmid identifica-
tion. It also tracks and synchronizes measurements of signals
over time, fits plasmid profiles, and allows nuclear identification.
The utility of CAPS was assessed with signals derived from
Visible EBV derivatives. These signal intensities revealed theirCell Host &near-Gaussian distribution over their radius following sub-
traction of the background found in an annulus of pixels
surrounding the signals (Figure 2B). CAPS also sums signals
and allows potential overlaps of signals from different fluores-
cent sources to be measured (Figure 2C), and provides a statis-
tical test of that potential overlap. This function has allowed us to
measure the possible overlap of fluorescently tagged proteins
with amplifying EBV DNA.
Visualization of the EBV DNAs during the Productive
Cycle
Cells carrying Visible Amplicon or Visible EBV were treated with
tamoxifen to observe EBV-derived DNAs transiting from latency
and progressing through the productive cycle. We used both a
sensitive CCD camera and an LED light source to minimize
phototoxicity (Frigault et al., 2009; Norby et al., 2012). In exper-
iments in which two colors were followed, the same field was
imaged about 10,000 times, and uninduced cells still progressed
through the cell cycle. These low light intensities limit resolution
but allowed us to identify whenwe should analyze fixed cells with
microscopy usingmore intense light to provide higher resolution.
The Visible Amplicon has the advantage of containing approxi-
mately five sets of lacO sites per EBV genome length, yielding
a more intense signal than does Visible EBV (Figures 1A, 1B,
3A, 3B, and S2A–S2C). However, it has the potential disadvan-
tage of being dependent on the EBV DNA endogenous to
iD98/HR1 cells which is invisible in our imaging experiments.
The Visible Amplicons in individual iD98/HR1 cells were imagedMicrobe 14, 607–618, December 11, 2013 ª2013 Elsevier Inc. 609
Figure 3. In Its Productive Phase EBV Reor-
ganizes the Nucleus with Viral DNA Amplifi-
cation often Occurring after Mitosis Early in
S Phase
(A) iD98/HR1(Visible Amplicon) cells were treated
with tamoxifen and followed over a 60 hr period.
The sum of the intensities of the fluorescent
signals in each nucleus for amplified Visible Am-
plicon was measured by CAPS.
(B) Another iD98/HR1(Visible Amplicon) cell
treated with tamoxifen first underwent a mitotic
division, and one of its daughter cells was tracked
over the next 24 hr (see also Figure S2 for exam-
ples in i293[Visible EBV] cells).
(C) The fraction of cells supporting EBV’s pro-
ductive cycle and going through mitosis or not is
tabulated.
(D–F) The time in the cell cycle at which EBV DNA
first amplified was determined by measuring LacI-
tdTomato signals and the intensities of introduced
Cdt1/eGFP in the same cells and normalizing the
maximum signal of Cdt1/eGFP for each cell cycle.
(D) The profiles of these intensities in uninduced
daughters shows minima at G2/M and maxima at
early S. (E) Intensities of Cdt1/eGFP and LacI-
tdTomato in induced iD98/HR1(Visible Amplicon)
cells that passed through mitosis prior to DNA
amplification show that amplification begins in
early S phase. The blue and purple plots show
Cdt1/eGFP signals in separate daughter cells; the
orange and green plots are signals in the daugh-
ters of one cell. (F) Tracking of DNA amplification
as a function of time after tamoxifen treatment in
three cells that did not pass through mitosis prior
to EBV amplification (see also Figure S2).
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conditions of minimal light exposure, the fluorescent signals
became intense by as early as 10–12 hr posttreatment with
tamoxifen and by 22 hr showed up to a 300-fold increase in
intensity as measured by CAPS (Figure 3A) (all measurements
made with CAPS are from raw data of 16 bit gray scales). EBV
DNA is synthesized in a licensed manner during latency so that
increases in its signal intensity above 2-fold indicate its produc-
tive amplification. The increased intensity of the Visible Amplicon
signals was paralleled by an increased expression of lytic genes
essential for the replication of EBVDNA, includingBRLF1 encod-
ing an immediate-early protein, BALF5 encoding EBV’s DNA
polymerase, BMRF1 encoding a viral DNA clamp, and BcLF1
encoding a major capsid protein (Figures S1E–S1H). The induc-
tion of the productive cycle was efficient; amplifying signals of
Visible Amplicons were detected in 60% of the cells that were610 Cell Host & Microbe 14, 607–618, December 11, 2013 ª2013 Elsevier Inc.treated with tamoxifen (Figure 3C). In
parallel, EBV’s DNA polymerase tran-
script increased by more than 6,000-fold
within 12 hr of the addition of tamoxifen
to the iD98/HR1 cells (Figure S1F).
The amplification of Visible EBV in indi-
vidual i293 cells was also tracked
following treatment with tamoxifen over
60 hr. The productively amplified VisibleEBV genomes were seen as pronounced fluorescent signals in
48% of the i293 cells (Figure 3C). The sum of the intensities for
the fluorescent signals in i293(Visible EBV) cells was determined
by CAPS, increased as early as 16–20 hr postinduction, and
grew 20-fold by 36 hr (Figure S2A). The increased intensity of
the Visible EBV signals could be detected only after removal of
IPTG (Figure S2D).
The signals of Visible Amplicon and Visible EBV also
increased in their diameters which were particularly evident for
the amplifying Visible Amplicon, consistent with more copies of
lacO sites being amplified per unit time for this replicon (Figures
1A, 1B, 3A, 3B, and S2A–S2C). These amplifying EBV derivatives
coalesced as islands either by accretion or by fusion with adja-
cent sites within nuclei at later times in the productive cycle (Fig-
ures 3A, 3B, 4C, 4D, 5A, 5B, S2A–S2C, S3A–S3C, and S4). The
architecture of these nuclei changed dramatically with their
Figure 4. Formation of EBV Amplification Factories Is Marked by PCNA
(A) In a iD98/HR1(Visible Amplicon) cell, treatment with tamoxifen leads to nuclei, becoming ‘‘honeycombed’’ hours before viral DNA is amplified by the redis-
tribution of LacI-tdTomato fusions.
(B) One i293(Visible EBV) cell expressing eGFP-PCNA was treated with tamoxifen and imaged over 40 hr. Multiple z planes at indicated time points are summed
and illustrated. The punctate structures of ectopic eGFP-PCNA-marked replication foci were detected in i293(Visible EBV) 16 hr posttreatment with tamoxifen,
subsequently were dispersed at 20 hr, and then were relocalized to the general sites at which EBV DNA was being amplified (see also Figure S3 for examples in
iD98/HR1[Visible Amplicon] cells).
(C) One i293(Visible EBV) cell that had been transduced to express eGFP-PCNA fusions was treated with tamoxifen to induce EBV’s productive cycle for 48 hr
followed by staining with Hoechst 33342 prior to fixation with paraformaldehyde. It was then imaged with a Zeiss Apotomemicroscope and shows that the Visible
EBV localized to regions of the nucleus unstained by Hoechst dye.
(D)Parallel experiments to those in (C)werecarriedoutwith eGFP-BALF5, EBV’sDNApolymerase thatmediatesDNAamplificationduringEBV’sproductivephase.
(E) The signals in (C) of eGFP-PCNA do not overlap with those of LacI-tdTomato as determined with CAPS (see Figure 2C for an explanation).
(F) The signals in (D) of eGFP-BALF5 do overlap with those of LacI-tdTomato as determined with CAPS (see also Figure S3).
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Similar changes in nuclear architecture occurred in B cells
induced to support EBV’s lytic cycle (Figures S5A and S5B), illus-Cell Host &trating the generality of EBV’s appropriating cellular functions for
its lytic cycle. Finally no fluorescent signals were detected in the
cytoplasm after treatment with tamoxifen (Figures 3A, 3B, 4B,Microbe 14, 607–618, December 11, 2013 ª2013 Elsevier Inc. 611
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EBV Programs the Nucleus for Its AmplificationS2A–S2C, S3A, S3B, and S4A–S4C), indicating either that the
LacI-tdTomato fusions were removed from lacO sites prior to
DNA encapsidation or too few were retained to be detected.
The Time of the Amplification of EBV during the Cell
Cycle
Visible Amplicon or Visible EBV derivatives were visualized as
fluorescent signals with increasing intensities during the produc-
tive cycle. Within a single cell, amplification of all plasmids
became detectable during the course of 1–2 hr (Figures 3A,
3B, 4A, 4B, 5A, S2A–S2C, S3A, S3B, and S4A–S4C). In some
cells that supported the productive cycle, the EBV derivatives
began to be amplified within a few hours after induction. How-
ever, in other cells amplification was detected only 30–36 hr
postinduction, longer than the generation time of either iD98/
HR1 or i293 cells (Figures 3B and S2C; data not shown). Of
iD98/HR1(Visible Amplicon) cells that supported the productive
cycle, 29% were seen to go through mitosis prior to amplifica-
tion. Amplification occurred approximately 10 hr after the cells
exited mitosis. Similarly, Visible EBV signals began to be
amplified detectably about 20 hr following mitosis in 24% of
i293(Visible EBV) cells supporting EBV’s productive cycle (Fig-
ure 3C). The timing of amplification was determined by analyzing
expression levels of a portion of Cdt1 fused to eGFP (Cdt1/
eGFP), which exhibited Cdt1’s characteristic cell-cycle depen-
dence in the same cells in which EBV DNA was amplifying
(Figures 3D–3F) (Nishitani et al., 2001; Sakaue-Sawano et al.,
2008). EBV DNA began to be amplified 1–3 hr after Cdt1/eGFP
reached 90% of its peak intensity corresponding to a time early
in S phase (Figures 3E and 3F). Once the EBV derivatives began
to be amplified, those cells that had passed through mitosis and
supported EBV’s productive cycle did not go through another
cell division (Figures 3B, S2B, S2C, and S3B). Thus EBV affects
passage of its host through its cell cycle, when necessary allow-
ing it to pass through mitosis, and arresting it in early S phase,
presumably to optimize the environment for amplification of its
genome. EBV also dramatically altered the morphology of its
host’s nucleus. One to several hours before EBV DNA amplifica-
tion could be detected in live cells the nuclei became mottled or
honeycombed, displaying subtle differences in the architecture
of the nucleus (Figure 4A). These initial subtle changes were de-
tected as approximately 0.5% local differences in the intensities
of LacI-tdTomato and then grew more profound as the viral ge-
nomes were amplified. The Lac repressor binds nonspecifically
throughout the human genome so that the detected differences
likely reflect differences in chromatin compaction (see below).
EBV DNA Is Amplified in Distinctive Factories
Chromosomal DNA is synthesized in replication factories that
can be detected by the localization of PCNA, the DNA clamp,
to them (Leonhardt et al., 2000). There are on the order of
1,000 of these factories per nucleus which form in S phase and
characteristically change their number and size during the
course of DNA synthesis (Leonhardt et al., 2000). These cellular
replication factories marked with eGFP-PCNA accumulated in
both untreated iD98/HR1 and i293 cells in early S phase, gave
rise to punctate perinuclear structures in mid-S phase, and
decreased in number toward the end of S phase (data not
shown). Unexpectedly, after treatment with tamoxifen, eGFP-612 Cell Host & Microbe 14, 607–618, December 11, 2013 ª2013 ElsPCNA-associated replication factories were detected in
i293(Visible EBV) cells at the beginning of S phase, subsequently
were dispersed for approximately 2 hr, and then relocalized to
the general sites at which EBV DNA was being amplified (Fig-
ure 4B). Similarly, eGFP-PCNA-associated replication factories
which formed prior to treatment with tamoxifen were dispersed
and relocalized generally to sites where Visible Amplicons were
amplified in treated iD98/HR1 as early as 8–10 hr posttreatment
(Figures S3A and S3B). The altered distribution of PCNA during
EBV’s DNA amplification was most apparent following fixation
and imaging with a Zeiss Apotome microscope which allows
removal of out-of-focus light but not live-cell imaging (Figures
4C and S3C). The frequent redistribution of PCNA to these
amplification factories was surprising, given that EBV encodes
its own DNA clamp, BMRF1, which is efficiently induced in these
cells (Figure S1G) and serves as the clamp for newly amplifying
EBV DNA (Makhov et al., 2004; Tsurumi et al., 1993b, 1994).
While PCNA often localized to the amplification factories, it
was not detected at the sites of viral DNA synthesis (Figures
4C and 4E) (see below).
EBV’s amplification factories were prominent in cells carrying
the Visible Amplicon or Visible EBV and engineered to express
histones H2B, H3.1, or H3.3, each tagged with eGFP. Following
treatment with tamoxifen to induce EBV’s productive cycle, the
positions of the amplifying viral DNAs gradually altered. These
alterations were visible in live cells (Figures 5A and S4A–S4C)
and could be observed particularly well following fixation and
imaging with a Zeiss Apotome microscope (Figures 5B and
S4D–S4H). These morphological changes consisted of the his-
tones and histone-bound chromosomal DNA, which was also
stained with Hoechst 33342 (data not shown), moving to the
margins of the nucleus and EBV’s amplification factories sepa-
rating from these margins. Similar morphological changes
occurred in B cells induced to support EBV’s lytic cycle (Figures
S5A and S5B). These morphological changes were inhibited by
68%with ganciclovir, which is activated by EBV’s protein kinase
BGLF4 and inhibits the function of EBV’s DNA polymerase (Fig-
ure 5C) (Meerbach et al., 1998; Meng et al., 2010).
EBV Uses Two Mechanisms to Evade the Loading of
Histones onto Its Amplifying DNA
The cell uses complex machinery to load histones onto newly
synthesized DNA laying down new chromatin adjacent to the
replications forks (MacAlpine and Almouzni, 2013). EBV some-
how evades this machinery because histones are not found on
its encapsidated DNA (Johannsen et al., 2004). To understand
how EBV avoids the deposition of histones, we first measured
the protein levels of the histone H2B and H3 in cells induced to
support the productive cycle and found the levels did not decline
(Figures 6A and 6B). We alsomeasured the level of eGFP-tagged
histones at the sites where EBV DNAs were being amplified.
While the intensities of the EBV DNA signals rose up to 36-fold
during the productive replication, the intensities of the histone
signals at the identical pixel sites varied due to noise but did
not increase over time (Figures 5A and S4A–S4C). These mea-
surements indicate that EBV escapes the loading of histones
at the time its genomes are being amplified.
To understand this avoidance of histone depositionmechanis-
tically, we measured the levels of constituents of the cellularevier Inc.
Figure 5. The Distributions of EBV Deriva-
tives and eGFP-Histone H2B Fusions Were
Tracked and Measured during the Produc-
tive Cycle
(A) iD98/HR1(Visible Amplicon) cells transduced to
express eGFP-histone H2B fusions were treated
with tamoxifen and tracked with time-lapse mi-
croscopy for 50 hr. Multiple z planes of live-cell
images at indicated time points are summed and
shown. The sum of intensities of eGFP-H2B fluo-
rescent signals (green circles) and red fluorescent
signals (red circles) for amplified Visible Amplicon
in identical volumes in live cells was determined
with CAPS and shows that over time eGFP-H2B
signals do not increase, whereas EBV DNA signals
do (additional examples of time-lapse measure-
ments are shown in Figure S4A).
(B) For higher resolution, similarly generated cells
were examined with a Zeiss Apotome microscope
following fixation with paraformaldehyde at the
indicated times after tamoxifen treatment.
(C) Inhibiting EBV’s DNA polymerase with gancy-
clovir following treatment with tamoxifen prevents
formation of 68%of the amplification factories that
are delineated by histone-bound chromatin (see
also Figure S4).
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productive cycle. While the protein levels of histone chaperones
HIRA, NAP1L1, and Daxx were stable throughout EBV’s produc-
tive cycle, the protein levels of the histone chaperones CAF-1a
and ASF1a decreased by 80% (Figures 6A and 6B), and the
mRNAs of CAF-1a, CAF-1b, and ASF1b decreased by 80%–
95% (Figure 6C). These four inhibited chaperones normally
contribute to deposition of histones during DNA synthesis. We
asked whether, if they were added back to cells supporting
EBV’s productive cycle by the introduction of five expression
vectors for their subunits, they could now deposit a tagged his-
tone onto amplifying EBV DNA. The histone chaperones were
expressed (Figure S5D) but failed to deposit the tagged histones
(Figure S5C). Thus the inhibition of synthesis of histone chaper-
ones during EBV’s lytic cycle alone does not explain the failure of
histone deposition.
PCNA helps recruit histone chaperones to replicating DNA
(Sharp et al., 2001; Shibahara and Stillman, 1999). We therefore
assayed eGFP/PCNA for its position and found that it did not
colocalize with amplifying EBV DNA (Figures 4C and 4E), while
EBV’s DNA polymerase, BALF5, did (Figures 4D and 4F). Five
cells induced to amplify EBV DNA and expressing eGFP/PCNA
and five similarly induced and expressing eGFP/BALF5 were
assayed for their overlap of red and green signals with CAPS
(one each is shown in Figures 4E and 4F). The correlation coeffi-
cient of the red signal of EBV DNA with the green signal of PCNA
was 0.09 with a p value of 0.29, while that of EBV DNA with
BALF5 was 0.65 with a p value of 9 3 1010 (Spearman’s rank
correlation test; Experimental Procedures), confirming that
BALF5 overlapped with newly amplified EBV DNA but PCNA
did not. The amplification of EBV DNA is mediated by the EBV-
encoded DNA polymerase, BALF5, and the encoded DNA
clamp, BMRF1 (Tsurumi et al., 1993b). We found that these
two viral proteins lack the motifs known to support interactions
with PCNA, [QXX(V/L/M/I)XX(F/Y)(F/Y)] or [KA(A/L/I)(A/L/Q)Cell Host &XX(L/V)] (Jo´nsson et al., 1998; Maga and Hubscher, 2003; War-
brick, 2000), consistent with PCNA’s absence from the site of
EBV’s amplifying DNA. Thus during EBV’s lytic cycle, PCNA is
replaced by independently acting viral machinery and is not in
a position to interact with the chaperones needed to deposit
histones on the viral DNA. This absence, along with the dimin-
ished levels of the chaperones themselves, ensure that EBV
can amplify its DNA independently of the cellular machinery
that deposits histones onto newly synthesized DNA.
DISCUSSION
We have developed visible derivatives of EBV, an efficient way to
induce their productive cycle, and photometry software to char-
acterize EBV’s transition in real time from latency through its
genome amplification in the productive phase. The combination
of these approaches has uncovered unprecedented changes in
nuclear structure and cellular replication machinery that are
mediated by the virus as it makes this transition.
We have used a fusion of Cdt1 to eGFP to define passage
through the cell cycle in live cells (Sakaue-Sawano et al., 2008)
following efficient induction of EBV’s productive cycle. About
30%of these cells went throughmitosis before EBVDNAs began
to be amplified. In these cells the viral DNA signals increased in
intensity 10–20 hr after mitosis. The remainder of the cells
supported the amplification without going through mitosis.
These observations mean that a functional BZLF1 sufficient to
induce EBV’s productive phase does not drive the cells into a
G0/G1 arrest as has been found previously (Cayrol and Fleming-
ton, 1996). Instead, the measurements with Cdt1/eGFP show
that EBV DNA began to be detectably amplified in early S phase.
The sequential measurements in live cells establish that, when
necessary, EBV conditions its entry into its lytic phase by delay
during a cell cycle to allow it to exploit its host’s environment
in early S phase (Kudoh et al., 2009).Microbe 14, 607–618, December 11, 2013 ª2013 Elsevier Inc. 613
Figure 6. The Expression of Histones and Their Chaperones Was Measured during EBV’s Productive Cycle in iD98/HR1(Visible Amplicon)
Cells
(A) Gels illustrate measurements of proteins detected by immunoblotting as a function of time after treatment of cells with tamoxifen.
(B) Averages of three independent experiments like those shown in (A) ±SD were measured with ImageJ software. The expression levels of proteins were
normalized to that of a-tubulin and then compared to the expression levels in the absence of tamoxifen, which were arbitrarily set to 1.
(C) Levels of transcribed mRNA of histones and their chaperones after treatment with tamoxifen were quantified by qPCR. Data are the average of three in-
dependent experiments. The expression levels were normalized to the expression of mRNA for GAPDH and then compared to the expression levels in the
absence of tamoxifen which was arbitrarily set to 1 (see also Figure S5 for extensions to other cell types for the expression of histones and histone chaperones
during EBV’s productive cycle).
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EBV Programs the Nucleus for Its AmplificationThe sequential remodeling of the nucleus found during
EBV’s transitioning to its lytic phase was unexpected. Several
hours before viral DNA was amplified in any cell, its nucleus
became subtly honeycombed. These initial changes reflect
small variations in concentrations of LacI-tdTomato binding
nonspecifically to host DNA and arise, we hypothesize, as
initial stages of the recession of cellular chromatin to the
nuclear margins we observed later in the same calls. The dis-
position of amplifying EBV plasmids during EBV’s productive
cycle was particularly revealing in the presence of fluores-
cently labeled histones. EBV’s amplification factories were
separated from the histone-bound chromosomal DNA that gr-
adually moved to the margins of the nuclei. These amplification
factories look similar to loci described for HSV-1 in infection of
HeLa cells in which the volume occupied by chromosomal
DNA decreased dramatically during productive infection (Monier
et al., 2000).614 Cell Host & Microbe 14, 607–618, December 11, 2013 ª2013 ElsIt is not clear how EBV’s amplification factories form, but they
are marked by PCNA (Daikoku et al., 2006; Sugimoto et al.,
2011). We have found that EBV’s productive cycle mediates a
complex, sequential redistribution of PCNA. As EBV transits
into later times in its lytic phase, PCNA collects in or near viral
amplification factories but is not concentrated at the sites at
which EBV DNA is being amplified. Its absence at these sites
reflects EBV’s DNA clamp encoded by its BMRF1 gene being
required at these sites (Tsurumi et al., 1993a). In addition, while
the BMRF1 protein does interact with EBV’s DNA polymerase,
BALF5, both BMRF1 and BALF5 lack the sequence motifs
known to mediate an interaction with PCNA consistent with
EBV’s genome amplification being independent of PCNA (Jo´ns-
son et al., 1998; Kiehl and Dorsky, 1995; Maga and Hubscher,
2003; Warbrick, 2000).
Another unanticipated insight into EBV’s productive cycle
came from following the distribution of eGFP-labeled histonesevier Inc.
Figure 7. Molecular Events Define EBV’s
Transition from Its Latent to Its Productive
Cycle
Following infection and entry of EBV’s genome into
the nucleus, it circularizes through terminal repeats
and is wrapped by histones as an extrachromo-
somal plasmid. In the latent phase of EBV life cycle,
its genome is licensed and replicates via oriP
bidirectionally in S phase as a plasmid, whereas in
the productive phase, amplification of EBV’s DNA
is unlicensed and waits until early S phase to begin
when the expression of eGFP-Cdt1 is maximal.
Once EBV’s productive cycle is activated by im-
mediate-early (IE) proteins, the viral genome is
replicated efficiently via oriLyt L and R eventually
as a polymer, perhaps through a rolling circle
mechanism. This replication occurs in discrete
factories in which the cellular clamp PCNA is re-
distributed and fromwhich chromatin and histones
are excluded. EBV’s productive cycle inhibits the
synthesis of histone chaperones CAF-1a, CAF-1b,
ASF1a, and ASF1b. EBV’s DNA clamp, BMRF1,
mediates amplification, ensuring that PCNA does
not localize to the site of amplification and cannot
recruit residual chaperones to newly synthesized
DNA. The replicated EBV genomes in association
with polyamines are packaged into capsids.
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EBV Programs the Nucleus for Its AmplificationH2B, H3.1, or H3.3 relative to the amplifying viral DNA. No
increase in the levels of these histones was observed to be asso-
ciated with the increasing signals of amplifying EBV DNAs, indi-
cating either that they are not being loaded onto the amplified
DNA or are being loaded inefficiently. We found that EBV uses
two mechanisms to evade cellular machinery that deposits his-
tones onto its newly synthesized DNA. First, we found that the
levels of protein or mRNA for the cellular histone chaperones,
CAF-1a, CAF-1b, ASF1a, and ASF1b, declined by 72 hr to
5%–20% of the levels found at the beginning of the productive
cycle. These observations indicate that EBV’s productive cycle
is inhibiting the synthesis of these chaperones that are involved
in cell-cycle-dependent deposition of histones. Second, EBV’s
replacement of PCNA with its own DNA clamp means that
PCNA is not positioned to recruit any remaining chaperones to
sites of viral DNA amplification. We also found that EBV’s
productive cycle does not affect levels of the chaperonesCell Host & Microbe 14, 607–618, DNAP1L1, HIRA, and Daxx, which
contribute to the loading of histones for
transcription-coupled deposition (Lewis
et al., 2010; Mosammaparast et al.,
2002; Okuwaki et al., 2005; Tagami
et al., 2004). Nor does EBV affect levels
of PCNA, which is required for recruiting
histone chaperones along with histones
to the replication fork for their deposition
on newly synthesized cellular DNA
(Moggs et al., 2000; Shibahara and Still-
man, 1999). We assume that some viral
templates are bound by nucleosomes in
order to be transcribed by RNA poly-
merase II, as has been found for HSV-1(Kutluay and Triezenberg, 2009). Where these nucleosome-
bound viral DNAs are in the nucleus is not known.
EBV supports both a latent and a lytic or productive phase in
cell culture (Figure 7). Its latent origin of DNA synthesis, oriP
(Shirakata et al., 1999; Yates et al., 1984), gives way to two ori-
gins, oriLyt L and R, used by viral proteins to mediate unlicensed
amplification during EBV’s productive cycle (Hammerschmidt
and Sugden, 1988, 2013; Pfu¨ller and Hammerschmidt, 1996;
Tsurumi, 2001). Following EBV DNA visually has shown that its
amplification is often delayed until the ensuing cell cycle,
ensuring it occurs in early S phase. EBV remodels nuclei to
house discrete factories in which viral DNA is amplified. Late in
this productive phase cellular chromatin is compacted and
moves to the periphery of the nucleus. The separation of viral
amplification factories from chromatin is highlighted by the redis-
tribution of PCNA and the exclusion of histones from those
factories. Thus EBV transits from a stable coexistence duringecember 11, 2013 ª2013 Elsevier Inc. 615
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EBV Programs the Nucleus for Its Amplificationlatency to hijacking nuclear functions and architecture tomeet its
reproductive needs.EXPERIMENTAL PROCEDURES
Generating Inducible Cell Lines with Visible Amplicon or Visible EBV
D98/HR1 and 293 cells were transduced to express a tamoxifen-inducible
BZLF1 derivative (Z-ER) and selected with 1 mg/ml of puromycin. p4012(Visible
Amplicon) was transfected into iD98/HR1 cells, and p4016(Visible EBV) was
transfected into i293 cells. G418- or hygromycin-resistant clones, respec-
tively, were selected. The released encapsidated DNAs of Visible Amplicon
or Visible EBV from these clones were measured by qPCR to select for those
supporting the complete productive cycle. Primers and probes used to quan-
tify viral DNAs are listed in Table S1.Time-Lapse Experiments
Time-lapse experiments were performed with an image system using a Zeiss
Axiovert 200M microscope as described (Norby et al., 2012). Between 60 and
86 planes were sampled at intervals of 0.35–0.4 mm for each z plane, each 60–
120 min over 48–72 hr. Exposure times ranged from 50 to 200 ms for red and
5–50 ms for green signals and were chosen to allow detection of signals with
minimal exposures. All images were taken with a Plan-Apochromat 633, 1.4
NA oil objective, and a Cascade II 1024 EMCCD camera (Photometrics) with
a 16 bit dynamic range. No images were saturated as judged by their most
intense pixels being less than half of approximately 65,000 gray levels. Images
at the indicated times following treatment with tamoxifen are displayed as the
square of maximum intensity projections across the z planes, with the mini-
mum intensity mapped to 0 and the maximum to 1. Channels were combined
in ImageJ.Quantification of Intensity of Fluorescence Signals by CAPS
CAPS is a web-based application designed to aid in the selection and
measurement of microscopy images captured on a CCD camera. Collections
of images, displayed in the x-y plane, can be navigated in the z and time
dimensions. CAPS measures the sum of all pixels using only raw data within
the radius of the signal and subtracts the average value of the pixels in the
surrounding one-pixel annulus from each pixel, thereby removing the influ-
ence of the background. The background annuli are chosen visually to
encompass >90% of the signal at the most intense z level as measured by
Gaussian fitting. The value is summed for each of one to ten z levels spanned
by the signal. CAPS is described fully at http://caps.grapheasy.org. CAPS
determines overlap by calculating the ratio of the average pixel intensity of
a signal divided by the average pixel intensity of its surrounding annulus.
Then, using Spearman’s rank correlation coefficient, a user measures the
correlation of the ratios between one colored signal and another for multiple
pairs across multiple images. No overlap between the signals in the two
channels would appear uncorrelated, while overlapping signals appear
correlated.Measuring Intensities of Fluorescence Signals in Nuclei
To determine the change of intensity of fluorescent signals in nuclei over the
cell cycle (for example, that of eGFP-Cdt1), we outlined the nucleus and
determined the average pixel intensity within the outline. To identify the
edge of the nucleus, we first defined a circle that completely surrounded the
nucleus. Then we used active contours or ‘‘snakes,’’ a computer vision algo-
rithm that constricts the circle until each point along the circle has hit an
edge or contour, to define the nuclear edge. This was done using the spline-
Snake plugin (http://bigwww.epfl.ch/jacob/software/SplineSnake/) for ImageJ
and a custom macro for determining averages over time.SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures, one table, and Supplemental
Experimental Procedures and can be found with this article at http://dx.doi.
org/10.1016/j.chom.2013.11.009.616 Cell Host & Microbe 14, 607–618, December 11, 2013 ª2013 ElsACKNOWLEDGMENTS
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